For: | Gao YP, Li L, Yan J, Hou XX, Jia YX, Chang ZW, Guan XY, Qin YR. Down-Regulation of CIDEA Promoted Tumor Growth and Contributed to Cisplatin Resistance by Regulating the JNK-p21/Bad Signaling Pathways in Esophageal Squamous Cell Carcinoma. Front Oncol 2020;10:627845. [PMID: 33614508 DOI: 10.3389/fonc.2020.627845] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis] |
---|
Number | Citing Articles |
1 | Tavares NT, Gumauskaitė S, Lobo J, Jerónimo C, Henrique R. DNA Methylation Biomarkers for Prediction of Response to Platinum-Based Chemotherapy: Where Do We Stand? Cancers (Basel) 2022;14:2918. [PMID: 35740584 DOI: 10.3390/cancers14122918] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis] |
2 | Zorzan E, Elgendy R, Guerra G, Da Ros S, Gelain ME, Bonsembiante F, Garaffo G, Vitale N, Piva R, Marconato L, Aresu L, Dacasto M, Giantin M. Hypermethylation-Mediated Silencing of CIDEA, MAL and PCDH17 Tumour Suppressor Genes in Canine DLBCL: From Multi-Omics Analyses to Mechanistic Studies. Int J Mol Sci 2022;23:4021. [PMID: 35409379 DOI: 10.3390/ijms23074021] [Reference Citation Analysis] |
3 | Luo Y, Wu Y, Huang H, Yi N, Chen Y. Emerging role of BAD and DAD1 as potential targets and biomarkers in cancer. Oncol Lett 2021;22:811. [PMID: 34671425 DOI: 10.3892/ol.2021.13072] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis] |